News | 12 September 2025
Aarti Drugs receives order from MPCB for closure of process at Tarapur unit
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
CRISPR-based detection enables highly specific molecular recognition
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Hemant Surgical Industries receives order
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Mansam, founded in 2022, is positioned as the first Arabian luxury fragrance brand with a vision for global expansion
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
The facility has been designed with a dual focus on efficiency and sustainability
The payment is in accordance with the agreed contractual terms
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Subscribe To Our Newsletter & Stay Updated
